Cook completes drug-coated stent trial enrolments:
This article was originally published in Clinica
Executive Summary
Cook has completed the enrolment phase of two major multicentre clinical trials of its drug-coated coronary stent. The trials are being conducted in Asia and Europe and are designed to assess the company's paclitaxel-coated stent for reducing restenosis. Both studies are randomised and prospective, each involving 180 patient. Cook of Bloomington, Indiana, also says that a US trial of its Logic stent coated with the drug is expected to start in around two months.